Suppiah Vijayaprakash, Lim Chiao Xin, Hotham Elizabeth
School of Pharmacy and Medical Sciences, University of South Australia, City West Campus, Adelaide, SA 5000, Australia.
Aust J Prim Health. 2018 Jan;24(6):441-447. doi: 10.1071/PY18047.
Patients obtaining a prescription from a pharmacy expect that the drug will be effective and have minimal side-effects. Unfortunately, drugs exhibit the desired effect in ~25-60% of people prescribed any medication. Adverse effects occur at a rate of 10% in patients taking a medication, and this rate increases during and after hospitalisation, with the transition of care back to the ambulatory setting posing a particular risk. Pharmacogenomics testing has been shown to optimise pharmacotherapy by increasing medication effectiveness and reducing drug-related toxicity, thus curtailing overall healthcare costs. Evidence from international studies have shown that community pharmacists would be able to offer this highly relevant professional service to their clients, given suitable training. This specific training complements pharmacists' existing skills and expertise by educating them in an emerging scientific area of pharmacogenomics. However, in an increasingly tight financial climate, the provision of pharmacogenomics testing by Australian community pharmacists will only be viable with an appropriate reimbursement through the Medicare Benefits Schedule, currently accessible by other allied health practitioners but not by pharmacists.
从药房拿到处方的患者期望药物有效且副作用最小。不幸的是，在开具任何药物处方的人群中，约25% - 60%的人药物能产生预期效果。服用药物的患者出现不良反应的发生率为10%，且在住院期间及出院后这一发生率会上升，转回门诊护理时存在特别风险。药物基因组学检测已被证明可通过提高药物疗效和降低药物相关毒性来优化药物治疗，从而降低总体医疗成本。国际研究证据表明，给予适当培训后，社区药剂师能够为其客户提供这项高度相关的专业服务。这种特定培训通过在新兴的药物基因组学科学领域对药剂师进行教育，补充了他们现有的技能和专业知识。然而，在日益紧张的财政环境下，澳大利亚社区药剂师只有通过医疗保险福利计划获得适当报销，才能提供药物基因组学检测服务，目前其他相关健康从业者可使用该计划报销，而药剂师不行。
